Suppliers / Yaopharma

Yaopharma

China Updated 9 July 2026

Yaopharma is a finished-dose manufacturer based in China. It appears in 15 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA and UZPHARM (UZ). Its most recent recorded inspection, by US FDA, closed on 29 March 2019 as VAI.

0
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
15
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 March 2019 VAI US FDA
  • 29 January 2016 NAI US FDA
  • 11 July 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3008309828

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 12 None
UZPHARM (UZ) 3 None

Questions about Yaopharma

Does Yaopharma hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Yaopharma. It does have 15 filings with 2 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
Is Yaopharma FDA-registered?
One site operated by Yaopharma carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Yaopharma's last inspection go?
The most recent inspection on record closed on 29 March 2019 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Yaopharma manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
Where does Yaopharma file?
Filings are on record with US FDA and UZPHARM (UZ), 15 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Yaopharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 March 2019.

Comparable suppliers

Astrazeneca Pharmaceutical also in China Changzhou Syntheall Pharmaceutical also in China Changzhou Yinsheng Pharmaceutical also in China Chengdu Shuode Pharmaceutical also in China Chia Tai Tianqing Pharmaceutical Group also in China

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability